Colorectal Neoplasms clinical trials

The registry lists 6,541 studies for Colorectal Neoplasms across more than 10 countries. 1,667 are recruiting or about to start. 4,872 of them are mainly about Colorectal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 8 narrower conditions too, such as Colonic Neoplasms: 10,042 studies, 2,664 open.

ClinicalTrials.gov finds 10,384 studies for Colorectal Neoplasms. How that becomes 6,535 here

This page counts the studies the registry files under Colorectal Neoplasms, and those it files under no condition that list Colorectal Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

10,384Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−3,270Filed under a narrower condition, counted on its own pageRectal Neoplasms 1,614 · Colonic Neoplasms 1,241 · Anus Neoplasms 214 · Colorectal Neoplasms, Hereditary Nonpolyposis 94 · Adenomatous Polyposis Coli 67 · Sigmoid Neoplasms 5 · 1 more
−99List Colorectal Neoplasms as a condition, but the registry did not file them under itMost often written as “Colorectal Cancer Metastatic” (24), “Colorectal Cancer Screening” (9), and “Microsatellite Stable Colorectal Cancer” (8). The registry filed them under other conditions only, most often Carcinoma, Non-Small-Cell Lung (22) and Neoplasms (18).
−485Match it another way231 name it in the title, 30 in a keyword, and 224 by a synonym or other text the search reads.
6,530Counted here and found by its search399 of them list Colorectal Neoplasms in their own words; the registry filed them under no condition.
+5
Counted here, but its search does not find them
6,535The count on this page

Get an email when these change. Save the Colorectal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 2,851
Recruiting: 1,185
Status unknown: 878
Terminated: 535
Not yet recruiting: 425
Active, not recruiting: 395

Phase

Phase 2: 2,053
Phase 1: 1,306
Phase 3: 548
Phase 4: 113
Early Phase 1: 61

Where

United States: 2,338
China: 1,132
France: 581
Spain: 461
Italy: 427
United Kingdom: 387

Who runs them

Fudan University (127) · M.D. Anderson Cancer Center (100) · Sun Yat-sen University (95) · National Cancer Institute (NCI) (93) · Hoffmann-La Roche (83) · Memorial Sloan Kettering Cancer Center (69) · Pfizer (53) · Alliance for Clinical Trials in Oncology (45)

What is being tested here

Drugs under test in Colorectal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Bevacizumab	38	46	214
HMPL-013	30	4	52
Cetuximab	27	33	171
Irinotecan	24	27	188
Capecitabine	22	36	168
Oxaliplatin	19	40	197
Fluorouracil	14	41	152
Folfox protocol	12	8	35
Sintilimab	11	3	20
Regorafenib	10	7	52

Drug classes tested here Immune checkpoint inhibitors 130 open · Antimetabolites 63 open · Tyrosine kinase inhibitors (TKIs) 57 open · Angiogenesis inhibitors 39 open · Antibody-drug conjugates (ADCs) 12 open

Coming up

145phase 3 studies under way

573studies finish main data collection within a year19 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer · Phase 3 · Shanghai Kechow Pharma, Inc.
Dec 2026Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis · Phase 3 · Ain Shams University
Dec 2026Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer · Phase 3 · Second Affiliated Hospital, School of Medicine, Zhejiang University
Dec 2026A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC · Phase 3 · Sun Yat-sen University
Dec 2026Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients · Phase 3 · Sun Yat-sen University
Dec 2026Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer · Phase 3 · City Clinical Oncology Hospital No 1
Mar 2027A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer · Phase 3 · Seattle Project Corporation
Mar 2027EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) · Phase 3 · University Hospital, Caen
Mar 2027Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer · Phase 3 · City of Hope Medical Center
Mar 2027Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer · Phase 3 · Fudan University

Who these studies take

Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger. 48 (4%) take children under 18. 3 (<1%) are for women only and 1 (<1%) for men only; 123 (10%) take healthy volunteers.

Recruiting studies that take each age, of 1,185
Age	Women	Men
10	34 (3%)	34 (3%)
18	1,058 (89%)	1,055 (89%)
30	1,098 (93%)	1,095 (92%)
40	1,119 (94%)	1,117 (94%)
50	1,157 (98%)	1,155 (97%)
65	1,157 (98%)	1,155 (97%)
75	1,091 (92%)	1,089 (92%)
85	841 (71%)	838 (71%)

Across all 6,541 studies, recruiting or not: 21% stop at 75 or younger and 3% at 65; 5% take children; 1% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Colorectal Neoplasms studies take

Of 618 phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	48 mo31–69 · 434 studies	47 mo31–66 · 268 studies	49 mo31–74 · 166 studies
Phase 1/2	59 mo36–87 · 260 studies	59 mo41–82 · 158 studies	57 mo36–106 · 102 studies
Phase 2	49 mo31–75 · 618 studies	34 mo26–72 · 120 studies	55 mo33–75 · 498 studies
Phase 2/3	56 mo44–105 · 36 studies	—	—
Phase 3	50 mo35–79 · 175 studies	43 mo26–54 · 69 studies	65 mo42–116 · 106 studies
Phase 4	49 mo29–57 · 38 studies	—	—
Interventional, no phase	32 mo14–60 · 955 studies	16 mo9–35 · 57 studies	32 mo15–62 · 898 studies
Observational	51 mo27–104 · 645 studies	45 mo30–60 · 117 studies	56 mo27–132 · 528 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out